MRK — Merck KGaA | ScreenerHero

MRKMerck KGaA

XETRA · DE · Healthcare · Drug Manufacturers - Specialty & Generic · emdgroup.com

120.75EUR-0.33%Mkt Cap: 51.02B EURP/E: 20.13Last update: 2026-05-14

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic…

Industry Peers

Drug Manufacturers - Specialty & Generic

SOBI

Swedish Orphan Biovitrum AB (publ)

153.14BSEKP/E 167.7

ECILC

EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.

Turk Ilac Ve Serum Sanayi Anonim Sirketi

3.09BTRY—

ROVI

Laboratorios Farmaceuticos Rovi, S.A.

3.02BEURP/E 25.0

DMP

Dermapharm Holding SE

2.79BEURP/E 24.1

loading…

Indicators:|

Key Statistics

Valuation

P/E (Trailing)20.13

P/E (Forward)13.67

PEG2.61

P/B1.71

P/S2.43

EV/EBITDA10.44

EV/Revenue2.83

EPS (TTM)5.83

EPS (Forward)8.59

Cash Flow & Leverage

FCF Yield6.04%

FCF Margin14.70%

Operating CF3.93B EUR

CapEx (TTM)1.96B EUR

Net Debt/EBITDA1.46

Net Debt8.26B EUR

Technical

SMA 50111.04 (+8.7%)

SMA 200115.79 (+4.3%)

Beta0.78

S&P 52W Chg24.23%

Avg Vol (30d)356.29K

Avg Vol (10d)337.57K

Technical Indicators

RSI (14)63.4

MACD1.2113

MACD Signal0.2597

MACD Hist.+0.9516

BB Upper121.36 EUR

BB Middle113.84 EUR

BB Lower106.32 EUR

BB Width13.22%

ATR (14)4.352 EUR

Vol Ratio (20d)0.88x

52W Range

100.7065% of range131.65

52W High131.65 EUR

52W Low100.70 EUR

Profitability

Gross Margin58.51%

EBITDA Margin27.08%

Profit Margin12.36%

Oper. Margin18.22%

ROE9.12%

ROA5.06%

Revenue Growth-2.80%

Earnings Growth-10.10%

Balance Sheet

Debt/Equity0.42

Current Ratio1.51

Quick Ratio0.92

Book Value/Sh68.56 EUR

Cash/Share8.700 EUR

Dividends

Fwd Div Rate2.200 EUR

Trail. Div Rate2.200 EUR

Div. Yield1.87%

5Y Avg Yield1.34%

Payout Ratio37.74%

Ex-Div DateApr 27, 2026

Pay Date—

Splits

Last Split2:1

Split DateJun 30, 2014

Ownership

Shares Out.129.24M

Float128.95M

Insiders0.00%

Institutions57.58%

Analyst Consensus

Rating1.8 (Buy)

Target (Mean)141.40 EUR

Target Range112.00 EUR – 179.00 EUR

# Analysts15

Company

Market Cap51.02B EUR

Enterprise Value59.25B EUR

Revenue (TTM)20.96B EUR

Gross Profit12.35B EUR

Net Income (TTM)2.61B EUR

Revenue/Share48.23 EUR

Fiscal Year EndDec 2025

MR QuarterMar 2026

Employees59.1K

Last Price120.75 EUR

CountryDE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISINUS5893392093